US 12,226,402 B2
Dual inhibitors of TIM-3 and PD-1 pathways
Pottayil Govindan Nair Sasikumar, Bangalore (IN); Muralidhara Ramachandra, Bangalore (IN); Seetharamaiah Setty Sudarshan Naremaddepalli, Bangalore (IN); and Nagaraj Gowda, Bangalore (IN)
Assigned to Aurigene Oncology Limited, Bangalore (IN)
Filed by Aurigene Oncology Limited, Bangalore (IN)
Filed on Nov. 21, 2023, as Appl. No. 18/516,458.
Application 18/516,458 is a continuation of application No. 17/962,096, filed on Oct. 7, 2022, abandoned.
Application 17/962,096 is a continuation of application No. 16/761,162, granted, now 11,497,734, previously published as PCT/IB2018/058526, filed on Oct. 31, 2018.
Claims priority of application No. 201741039298 (IN), filed on Nov. 3, 2017.
Prior Publication US 2024/0100024 A1, Mar. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4245 (2006.01); A61K 31/454 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/4245 (2013.01) [A61K 31/454 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01)] 14 Claims
 
1. A method of modulating an immune response mediated by T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) activity in a subject, comprising administering to the subject a compound, wherein the compound is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.